ARIAD PHARMACEUTICALS INC's ticker is ARIA and the CUSIP is 04033A100. A total of 207 filers reported holding ARIAD PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 2.16 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $11,134,000 | -99.9% | 895,000 | +32.6% | 2.13% | +45.4% |
| Q3 2016 | $9,240,750,000 | +199959.5% | 675,000 | +8.0% | 1.47% | +79.0% |
| Q2 2016 | $4,619,000 | +20.5% | 625,000 | +4.2% | 0.82% | +7.8% |
| Q1 2016 | $3,834,000 | +42.6% | 600,000 | +39.5% | 0.76% | +87.4% |
| Q4 2015 | $2,688,000 | +7.0% | 430,000 | 0.0% | 0.41% | +1.5% |
| Q3 2015 | $2,511,000 | -32.5% | 430,000 | -4.4% | 0.40% | -10.5% |
| Q2 2015 | $3,722,000 | +16.7% | 450,000 | +16.3% | 0.45% | -16.9% |
| Q1 2015 | $3,189,000 | +16.9% | 387,000 | -2.5% | 0.54% | -31.9% |
| Q4 2014 | $2,727,000 | +19.4% | 397,000 | -6.1% | 0.79% | +18.1% |
| Q3 2014 | $2,284,000 | -8.1% | 423,000 | +8.5% | 0.67% | -9.2% |
| Q2 2014 | $2,484,000 | +29.6% | 390,000 | +64.0% | 0.74% | +28.2% |
| Q1 2014 | $1,917,000 | -59.8% | 237,810 | -66.0% | 0.58% | -69.2% |
| Q4 2013 | $4,774,000 | – | 700,000 | – | 1.87% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 12,850,000 | $175,916,000 | 40.51% |
| Consonance Capital Management LP | 8,695,742 | $119,045,000 | 11.46% |
| Tamarack Advisers, LP | 3,700,000 | $49,358,000 | 7.76% |
| Opaleye Management Inc. | 1,045,000 | $14,306,000 | 7.49% |
| Granite Point Capital Management, L.P. | 457,415 | $6,262,000 | 2.44% |
| Redmile Group, LLC | 2,138,471 | $29,276,000 | 2.33% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 206,010 | $2,820,000 | 2.17% |
| Palo Alto Investors LP | 2,587,617 | $35,424,000 | 2.06% |
| PRICE MICHAEL F | 940,000 | $12,869,000 | 1.71% |
| HighVista Strategies LLC | 638,086 | $8,735,000 | 1.62% |